Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Vaginal microbiome modulates topical antiretroviral drug pharmacokinetics.

Taneva E, Sinclair S, Mesquita PM, Weinrick B, Cameron SA, Cheshenko N, Reagle K, Frank B, Srinivasan S, Fredricks D, Keller MJ, Herold BC.

JCI Insight. 2018 Jul 12;3(13). pii: 99545. doi: 10.1172/jci.insight.99545.

2.

Herpes simplex viruses activate phospholipid scramblase to redistribute phosphatidylserines and Akt to the outer leaflet of the plasma membrane and promote viral entry.

Cheshenko N, Pierce C, Herold BC.

PLoS Pathog. 2018 Jan 2;14(1):e1006766. doi: 10.1371/journal.ppat.1006766. eCollection 2018 Jan.

3.

Differential Mechanisms of Tenofovir and Tenofovir Disoproxil Fumarate Cellular Transport and Implications for Topical Preexposure Prophylaxis.

Taneva E, Crooker K, Park SH, Su JT, Ott A, Cheshenko N, Szleifer I, Kiser PF, Frank B, Mesquita PM, Herold BC.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1667-75. doi: 10.1128/AAC.02793-15.

4.

An innate antiviral pathway acting before interferons at epithelial surfaces.

Iversen MB, Reinert LS, Thomsen MK, Bagdonaite I, Nandakumar R, Cheshenko N, Prabakaran T, Vakhrushev SY, Krzyzowska M, Kratholm SK, Ruiz-Perez F, Petersen SV, Goriely S, Bibby BM, Eriksson K, Ruland J, Thomsen AR, Herold BC, Wandall HH, Frische S, Holm CK, Paludan SR.

Nat Immunol. 2016 Feb;17(2):150-8. doi: 10.1038/ni.3319. Epub 2015 Nov 30.

PMID:
26595890
5.

Dynasore disrupts trafficking of herpes simplex virus proteins.

Mues MB, Cheshenko N, Wilson DW, Gunther-Cummins L, Herold BC.

J Virol. 2015 Jul;89(13):6673-84. doi: 10.1128/JVI.00636-15. Epub 2015 Apr 15.

6.

Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease.

Petro C, González PA, Cheshenko N, Jandl T, Khajoueinejad N, Bénard A, Sengupta M, Herold BC, Jacobs WR.

Elife. 2015 Mar 10;4. doi: 10.7554/eLife.06054.

7.

Herpes simplex virus type 2 glycoprotein H interacts with integrin αvβ3 to facilitate viral entry and calcium signaling in human genital tract epithelial cells.

Cheshenko N, Trepanier JB, González PA, Eugenin EA, Jacobs WR Jr, Herold BC.

J Virol. 2014 Sep 1;88(17):10026-38. doi: 10.1128/JVI.00725-14. Epub 2014 Jun 18.

8.

HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression.

Cheshenko N, Trepanier JB, Stefanidou M, Buckley N, Gonzalez P, Jacobs W, Herold BC.

FASEB J. 2013 Jul;27(7):2584-99. doi: 10.1096/fj.12-220285. Epub 2013 Mar 18. Erratum in: FASEB J. 2015 Jan;29(1):355.

9.

Virus-cell fusion as a trigger of innate immunity dependent on the adaptor STING.

Holm CK, Jensen SB, Jakobsen MR, Cheshenko N, Horan KA, Moeller HB, Gonzalez-Dosal R, Rasmussen SB, Christensen MH, Yarovinsky TO, Rixon FJ, Herold BC, Fitzgerald KA, Paludan SR.

Nat Immunol. 2012 Jun 17;13(8):737-43. doi: 10.1038/ni.2350.

10.

Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety.

Segarra TJ, Fakioglu E, Cheshenko N, Wilson SS, Mesquita PM, Doncel GF, Herold BC.

PLoS One. 2011;6(11):e27675. doi: 10.1371/journal.pone.0027675. Epub 2011 Nov 11.

11.

HSV usurps eukaryotic initiation factor 3 subunit M for viral protein translation: novel prevention target.

Cheshenko N, Trepanier JB, Segarra TJ, Fuller AO, Herold BC.

PLoS One. 2010 Jul 27;5(7):e11829. doi: 10.1371/journal.pone.0011829.

12.

Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety.

Wilson SS, Cheshenko N, Fakioglu E, Mesquita PM, Keller MJ, Herold BC.

Antivir Ther. 2009;14(8):1113-24. doi: 10.3851/IMP1463.

13.

Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety.

Mesquita PM, Cheshenko N, Wilson SS, Mhatre M, Guzman E, Fakioglu E, Keller MJ, Herold BC.

J Infect Dis. 2009 Aug 15;200(4):599-608. doi: 10.1086/600867.

14.

Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism.

Fakioglu E, Wilson SS, Mesquita PM, Hazrati E, Cheshenko N, Blaho JA, Herold BC.

J Virol. 2008 Oct;82(19):9337-44. doi: 10.1128/JVI.00603-08. Epub 2008 Jul 30.

15.

Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression.

Guzman EM, Cheshenko N, Shende V, Keller MJ, Goyette N, Juteau JM, Boivin G, Vaillant A, Herold BC.

Antivir Ther. 2007;12(8):1147-56. Erratum in: Antivir Ther. 2008;13(2):335.

PMID:
18240855
16.

Seminal plasma reduces the effectiveness of topical polyanionic microbicides.

Patel S, Hazrati E, Cheshenko N, Galen B, Yang H, Guzman E, Wang R, Herold BC, Keller MJ.

J Infect Dis. 2007 Nov 1;196(9):1394-402. Epub 2007 Sep 26.

PMID:
17922405
17.

Multiple receptor interactions trigger release of membrane and intracellular calcium stores critical for herpes simplex virus entry.

Cheshenko N, Liu W, Satlin LM, Herold BC.

Mol Biol Cell. 2007 Aug;18(8):3119-30. Epub 2007 Jun 6.

18.

Molecular umbrellas: a novel class of candidate topical microbicides to prevent human immunodeficiency virus and herpes simplex virus infections.

Madan RP, Mesquita PM, Cheshenko N, Jing B, Shende V, Guzman E, Heald T, Keller MJ, Regen SL, Shattock RJ, Herold BC.

J Virol. 2007 Jul;81(14):7636-46. Epub 2007 May 9.

19.

PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity.

Keller MJ, Guzman E, Hazrati E, Kasowitz A, Cheshenko N, Wallenstein S, Cole AL, Cole AM, Profy AT, Wira CR, Hogarty K, Herold BC.

AIDS. 2007 Feb 19;21(4):467-76.

PMID:
17301565
20.

Access to nectin favors herpes simplex virus infection at the apical surface of polarized human epithelial cells.

Galen B, Cheshenko N, Tuyama A, Ramratnam B, Herold BC.

J Virol. 2006 Dec;80(24):12209-18. Epub 2006 Sep 27.

21.

ACIDFORM inactivates herpes simplex virus and prevents genital herpes in a mouse model: optimal candidate for microbicide combinations.

Tuyama AC, Cheshenko N, Carlucci MJ, Li JH, Goldberg CL, Waller DP, Anderson RA, Profy AT, Klotman ME, Keller MJ, Herold BC.

J Infect Dis. 2006 Sep 15;194(6):795-803. Epub 2006 Aug 16.

PMID:
16941346
22.

PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.

Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A, Goldberg CL, Wallenstein S, Profy AT, Klotman ME, Herold BC.

J Infect Dis. 2006 Jan 1;193(1):27-35. Epub 2005 Nov 17.

PMID:
16323128
23.

The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies.

Yim KC, Carroll CJ, Tuyama A, Cheshenko N, Carlucci MJ, Porter DD, Prince GA, Herold BC.

J Virol. 2005 Dec;79(23):14632-9.

24.

Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection.

John M, Keller MJ, Fam EH, Cheshenko N, Hogarty K, Kasowitz A, Wallenstein S, Carlucci MJ, Tuyama AC, Lu W, Klotman ME, Lehrer RI, Herold BC.

J Infect Dis. 2005 Nov 15;192(10):1731-40. Epub 2005 Oct 13.

PMID:
16235171
25.

Focal adhesion kinase plays a pivotal role in herpes simplex virus entry.

Cheshenko N, Liu W, Satlin LM, Herold BC.

J Biol Chem. 2005 Sep 2;280(35):31116-25. Epub 2005 Jul 1.

26.

Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread.

Cheshenko N, Keller MJ, MasCasullo V, Jarvis GA, Cheng H, John M, Li JH, Hogarty K, Anderson RA, Waller DP, Zaneveld LJ, Profy AT, Klotman ME, Herold BC.

Antimicrob Agents Chemother. 2004 Jun;48(6):2025-36.

27.

Theta defensins protect cells from infection by herpes simplex virus by inhibiting viral adhesion and entry.

Yasin B, Wang W, Pang M, Cheshenko N, Hong T, Waring AJ, Herold BC, Wagar EA, Lehrer RI.

J Virol. 2004 May;78(10):5147-56.

28.

Herpes simplex virus triggers activation of calcium-signaling pathways.

Cheshenko N, Del Rosario B, Woda C, Marcellino D, Satlin LM, Herold BC.

J Cell Biol. 2003 Oct 27;163(2):283-93. Epub 2003 Oct 20.

29.

NP-1, a rabbit alpha-defensin, prevents the entry and intercellular spread of herpes simplex virus type 2.

Sinha S, Cheshenko N, Lehrer RI, Herold BC.

Antimicrob Agents Chemother. 2003 Feb;47(2):494-500.

30.

Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry.

Herold BC, Scordi-Bello I, Cheshenko N, Marcellino D, Dzuzelewski M, Francois F, Morin R, Casullo VM, Anderson RA, Chany C 2nd, Waller DP, Zaneveld LJ, Klotman ME.

J Virol. 2002 Nov;76(22):11236-44.

32.

A novel system for the production of fully deleted adenovirus vectors that does not require helper adenovirus.

Cheshenko N, Krougliak N, Eisensmith RC, Krougliak VA.

Gene Ther. 2001 Jun;8(11):846-54.

33.

[Enhancement of epidermal regeneration by recombinant vaccinia virus growth factor].

Petrov VS, Cheshenko IO, Omigov VV, Azaev MSh, Krendel'shchikov AV, Ovechkina LG, Cheshenko NV, Malygin EG.

Vestn Ross Akad Med Nauk. 1998;(3):38-42. Russian.

PMID:
9608276
34.

[Recombinant vaccinia virus expressing Japanese encephalitis virus protein E].

Cheshenko NV, Petrov VS, Protopopova EV, Netesova NA, Konovalova SN, Belavin PA, Loktev VB, Malygin EG.

Mol Gen Mikrobiol Virusol. 1997;(3):24-7. Russian.

PMID:
9297107
35.

[Expression of a synthetic gene for human angiogenin in a recombinant vaccinia virus].

Netesova NA, Petrova VS, Cheshenko NV, Chikaev NA, Malygin EG, Mertvetsov NP.

Bioorg Khim. 1995 Aug;21(8):608-11. Russian.

PMID:
8540901
36.

[Immunochemical analysis of Escherichia coli expression products of I3 and A2 genes of vaccinia virus strain L-IVL genome].

Chikaev NA, Muravlev AI, Cheshenko NV, Gutorov VV, Malygin EG.

Mol Biol (Mosk). 1993 Mar-Apr;27(2):299-304. Russian.

PMID:
8487760
37.

[Mapping the genes of the vaccinia virus, coding membrane proteins p34 and p40, by mRNA hybridization selection].

Cheshenko NV, Netesova NA, Muravlev AI, Malygin EG.

Mol Biol (Mosk). 1991 Nov-Dec;25(6):1492-6. Russian.

PMID:
1813796
38.

[Isolation and characteristics of vaccinia virus proteins associated with cell membranes of infected cells].

Cheshenko NV, Netesova NA, Malygin EG.

Mol Biol (Mosk). 1991 Jul-Aug;25(4):946-54. Russian.

PMID:
1795708
39.

[Molecular-biological study of vaccinia virus genome. III. Identification of the late gene product protein 36K from Hind-III-P-fragment of vaccinia virus strain L-IVP].

Riazankina OI, Shchelkunov SN, Muravlev AI, Cheshenko NV, Chikaev NA, Malygin EG.

Mol Biol (Mosk). 1990 Jul-Aug;24(4):977-83. Russian.

PMID:
2250686
40.

[The localization of the gene of the vaccinia virus that codes for the 36K major membrane protein].

Prikhod'ko GG, Cheshenko NV, Netesova NA, Kozhina EN, Totmenin AV, Lebedeva TV, Malygin EG, Vasilenko SK.

Dokl Akad Nauk SSSR. 1990;313(2):497-500. Russian. No abstract available.

PMID:
2289401

Supplemental Content

Loading ...
Support Center